Inhibition of runt related transcription factor 1 with Ro24-7429 improves lung function in experimental models of idiopathic pulmonary fibrosis
Authors:
Open Access
- 2 June 2026
- journal article
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Abstract
Idiopathic Pulmonary Fibrosis (IPF) is a life limiting disease with debilitating symptoms and limited therapeutic options. The development of IPF is a chronic process involving epithelial-to-mesenchymal transition (EMT), perpetuated by fibroblast proliferation and abnormal wound healing during which normal lung tissue is replaced with collagen impairing lung expansion and aeration. We targeted Runt-related transcription factor 1 (RUNX1), a transcription factor that coordinates EMT upon stimulation by key inflammatory mediators, such as TGF-β and TNF-α. In a previous investigation performed during the COVID19 pandemic, inhibiting RUNX1 with the small molecule inhibitor Ro24-7429 (Ro24), which has undergone testing in humans with a favorable side effect profile, was linked to a robust amelioration of lung fibrosis and decreased markers of fibrosis. In prior work utilizing Ro24, no studies of pulmonary function were performed and investigation of RUNX1 in human lung tissue was limited. Herein, we identified abnormally elevated RUNX1 in diseased human lung tissue of seven patients with IPF, implicating the transcription factor in the progression of the disease. Targeting RUNX1 with the small molecule inhibitor, Ro24 improved lung function and exercise tolerance in a murine model of bleomycin-induced pulmonary fibrosis. In comparison to the currently used clinical standards nintedanib and pirfenidone, Ro24 improved exercise tolerance in bleomycin-challenged mice. Thus, Ro24 has strong translational potential as a preventative therapy for patients with IPF.Keywords
Funding Information
- National Institutes of Health (5T32HL007734)
- National Institutes of Health (2T32DK007754-22)
- National Institutes of Health (5T32HL007734)
- Richard and Sandra Cummings Research Fellowship of the Beth Israel Deaconess Medical Center Department of Ophthalmology
- Michael Plantevin
- The Monte J. Wallace Ophthalmology Chair in Retina
- Open Philanthropy Project
- Good Ventures Foundation
- The Boston Children’s Hospital Vascular Biology Program
- The Boston Children’s Hospital Surgical Foundation
- The Hannah Lillie Fund
- The Maisie Ellis & Friends Fund
- The Luke Raymond Celaya Research Fund
This publication has 70 references indexed in Scilit:
- Nintedanib improves bleomycin-induced pulmonary fibrosis by inhibiting the Clec7a/SPP1 pathway in interstitial macrophagesCellular Signalling, 2025
- Proliferative vitreoretinopathy: an update on the current and emerging treatment optionsGraefe's Archive for Clinical and Experimental Ophthalmology, 2023
- A pneumonectomy model to study flow-induced pulmonary hypertension and compensatory lung growthCell Reports Methods, 2023
- Targeting Runt-Related Transcription Factor 1 Prevents Pulmonary Fibrosis and Reduces Expression of Severe Acute Respiratory Syndrome Coronavirus 2 Host MediatorsThe American Journal of Pathology, 2021
- Treatment of Experimental Choroidal Neovascularization via RUNX1 InhibitionThe American Journal of Pathology, 2020
- Single-Cell Deconvolution of Fibroblast Heterogeneity in Mouse Pulmonary FibrosisCell Reports, 2018
- The Role of Runx1 in Embryonic Blood Cell Formation2017
- Fibroblast—Extracellular Matrix Interactions in Tissue FibrosisCurrent Pathobiology Reports, 2016
- Regulation and Relevance of Myofibroblast Responses in Idiopathic Pulmonary FibrosisCurrent Pathobiology Reports, 2013
- The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?The International Journal of Biochemistry & Cell Biology, 2008